<DOC>
	<DOC>NCT01188317</DOC>
	<brief_summary>This randomized, double-blind, placebo-controlled, parallel group study will investigate the safety and tolerability, and the effect of aleglitazar in combination with ibuprofen on renal function, renin-angiotensin system and pharmacokinetics in healthy volunteers. Volunteers will be randomized to receive daily doses of aleglitazar or placebo in combination with ibuprofen. The anticipated time on study drug is 5 weeks.</brief_summary>
	<brief_title>A Study of Aleglitazar in Combination With Ibuprofen in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Ibuprofen</mesh_term>
	<criteria>Healthy volunteers, aged 40 to 65 years inclusive Body Mass Index (BMI) between 18 and 35 kg/m2 inclusive Females of childbearing potential must be willing to use two acceptable methods of contraception during the study and at least 3 months before start of the study Nonsmoker or currently smoking less than 5 cigarettes (or equivalent amount of other tobacco products) per day and is willing and able to stop smoking during the period in study center Volunteer drinks no more than 3 cups of coffee, tea or soft drinks per day and is willing and able to stop drinking coffee, tea and soft drinks during the period in study center Any clinically relevant abnormal laboratory test results at screening Volunteer has taken any prescribed, herbal or overthecounter medication within 2 weeks prior to first dosing A history of any clinical significant gastrointestinal, cardiovascular, musculoskeletal, endocrine, hematological, psychiatric, renal, hepatic, bronchopulmonary or neurological conditions or lipid disorders A positive test for human immunodeficiency virus (HIV1 or HIV2), hepatitis B or hepatitis C History of intolerance to nonsteroidal antiinflammatory drugs (NSAIDs) or aspirin, history of gastric or duodenal ulceration, personal or family history of abnormal clotting or bleeding</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>